Near real-time analysis of active distribution networks in a Digital Twin framework. A real case study

The growth of distributed generation and the need of increasing Distribution Network (DN) resilience is encouraging Distribution System Operators (DSO) to increase awareness about the real-time status of the network as well as to actively manage flexible energy resources for improving system performances. In this context, Digital Twin (DT) is an enabling technology for a low-cost distributed framework that supports DN management. DT in the power system can be exploited taking advantage of the successful experiences in other sectors (e.g., smart manufacturing and building automation). This article presents a real case study of a DT development and its integration with an existing DN. The DT system architecture is based on the recent standards whilst main DT components have been originally developed, enabling near real-time services such as data collection, state estimation, and flexibility calculator. The individual performances of the integrated tools and the reliability of DT were tested and validated during one month of continuous operation. During the operation, good service continuity and accuracy performances were reported. Results from the flexibility calculator show the effectiveness of the proposed strategies that can improve the energy efficiency of the DN by increasing local self-consumption of Renewable Energy Sources (RES) production

Tunability of the elastocaloric response in main-chain liquid crystalline elastomers

Materials exhibiting a large caloric effect could lead to the development of a new generation of heat-management technologies that will have better energy efficiency and be potentially more environmentally friendly. The focus of caloric materials investigations has shifted recently from solid-state materials towards soft materials, such as liquid crystals and liquid crystalline elastomers. It has been shown recently that a large electrocaloric effect exceeding 6 K can be observed in smectic liquid crystals. Here, we report on a significant elastocaloric response observed by direct elastocaloric measurements in main-chain liquid crystal elastomers. It is demonstrated that the character of the nematic to paranematic/isotropic transition can be tuned from the supercritical regime towards the first-order regime, by decreasing the density of crosslinkers. In the latter case, the latent heat additionally enhances the elastocaloric response. Our results indicate that a significant elastocaloric response is present in main-chain liquid crystalline elastomers, driven by stress fields much smaller than in solid elastocaloric materials. Therefore, elastocaloric soft materials can potentially play a significant role as active cooling/heating elements in the development of new heat-management devices

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

n/

Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach

Neoplasms with plasma cell differentiation may occasionally involve the skin. Cutaneous lesions may represent the first sign of an underlying systemic plasma cell malignancy, such as multiple myeloma, or the skin itself may be the primary site of occurrence of a hematological tumor with plasma cell differentiation. Starting from examples encountered in our daily practice, we discussed the diagnostic approach pathologists and clinicians should use when faced with cutaneous lesions with plasma cell differentiation. Cases of primary cutaneous marginal zone lymphoma, localized primary amyloidosis/amyloidoma, and cutaneous manifestations (secondary either to multiple myeloma or to plasmablastic lymphoma) are discussed, focusing on the importance of the adequate patient’s work-up and precise clinicopathological correlation to get to the correct diagnosis and appropriate treatment. The pertinent literature has been reviewed, and the clinical presentation, pathological findings, main differential diagnoses, treatment, and outcome of neoplasms with plasma cell differentiation involving the skin are discussed

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study

The efficacy of anthracycline- and taxane-based chemotherapy for perioperative treatment of breast cancer (BC) has been established. No superiority of a cytotoxic regimen has been demonstrated, provided that administration of an anthracycline and a taxane is warranted. The ASTER study was designed to investigate the safety of 6 months of perioperative chemotherapy with Doxorubicin and Paclitaxel, followed by Cyclophosphamide, Methotrexate, and 5-Fluorouracil. ASTER enrolled patients with cT2-3 N0-1 or pT1-2 N1-3 BC, from November 2008 to August 2011. Treatment consisted of Doxorubicin 60 mg/sm, Paclitaxel 200 mg/sm q21 (AT) for three cycles followed by Cyclophosphamide 600 mg/sm, Methotrexate 40 mg/sm, 5-Fluorouracil 600 mg/sm d1,8 q28 (CMF) for three cycles, in either neo-adjuvant or adjuvant setting. All HER-positive patients received targeted therapy with Trastuzumab for 1 year. Disease-free and overall survival (DFS and OS, respectively) were estimated according to Kaplan-Meier method. Three hundred and thirty patients were enrolled, where 77.9% of cases were treated in an adjuvant setting; 65.5% received breast conservative surgery, 72.4% axillary dissection. 75.5% of cases presented estrogen receptor positivity, 66.7% progesterone receptor positivity; 18.5% of patients presented HER2-positive BC, 16.1% triple negative disease. Twenty-eight (8.5%) developed grade III-IV hematologic toxicity; nine patients (2.7%) developed grade III neurological toxicity. Loco-regional DFS was 99.6% at 1 year, 97.1% at 5 years, 95.9% at 7 years. Corresponding distant DFS was 98.4%, 90.2%, and 88.8%. One, 5, and 7-year OS was 99.6%, 94.9%, and 91.2%, respectively. Chemotherapy with ATx3 -> CMFx3 is confirmed safe and effective at 6.7 years follow-up. These results appear comparable to those reported in regulatory trials of most commonly prescribed anthracycline and taxane-based regimens

Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-l1 monoclonal antibodies

Predictive biomarkers of response to immune-checkpoint inhibitors (ICIs) are an urgent clinical need. The aim of this study is to identify manageable parameters to use in clinical practice to select patients with higher probability of response to ICIs. Two-hundred-and-seventy-one consecutive metastatic solid tumor patients, treated from 2013 until 2017 with anti-Programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) ICIs, were evaluated for baseline lactate dehydrogenase (LDH) serum level, performance status (PS), age, neutrophil-lymphocyte ratio, type of immunotherapy, number of metastatic sites, histology, and sex. A training and validation set were used to build and test models, respectively. The variables\u2019 effects were assessed through odds ratio estimates (OR) and area under the receive operating characteristic curves (AUC), from univariate and multivariate logistic regression models. A final multivariate model with LDH, age and PS showed significant ORs and an AUC of 0.771. Results were statistically validated and used to devise an Excel algorithm to calculate the patient\u2019s response probabilities. We implemented an interactive Excel algorithm based on three variables (baseline LDH serum level, age and PS) which is able to provide a higher performance in response prediction to ICIs compared with LDH alone. This tool could be used in a real-life setting to identify ICIs in responding patients

Reseñas

Iotsald von Saint-Claude, Vita des Abtes Odilo von Cluny, ed. JOHANNES STAUB. JOHANNES STAUB, Studien zu Iotsalds Vita des Abtes Odilo von Cluny. ANDRÉ JOAO MARIA, Sentido, simbolismo e interpretacao no discurso filosófico de Nicolau de Cusa. WOFGANG D. FRITZ / WOFGANG EGGERT (ed), Monumenta Germaniae Historica. Constitutiones et acta publica imperatorum et regum tomi XI. Fasciculus VIII: Dokumente zur Geschichte des deutschen Reiches und seiner Verfassung 1354-1356. THOMAS FRENZ / PETER HERDE (ed), Das Brief- und Memorialbuch des Albert Behaim. ROMAN DEUTINGER / RAHEWIN VON FREISING, ein Gelehrter des 12. Jahrhunderts. UWE LUDWIG, Transalpine Beziehungen der Karolingerzeit im Spiegel der Memorialüberlieferung. Prosopographische und sozialgeschchtliche Studien unter besonderer Berücksichtigung des “Liber vitae” von San Salvatore in Brescia und des Evangeliars von Cividale. VALENTÍN CRICCO, Semiótica Agustiniana. El diálogo ‘El Maestro’ de san Agustín. VICTORIA CIRLOT / BLANCA GARÍ, La mirada interior. Escritoras místicas y visionarias en la Edad Media. IGNACIO ANGELELLI / PALOMA PÉREZ-ILZARBE (ed), Medieval and renaissance logic in Spain: acts of the 12th European Symposium on Medieval Logic and Semantics, held at the University of Navarre

A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors

This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation study assessed BI 860585 monotherapy (5–300 mg/day; Arm A), BI 860585 (40–220 mg/day; Arm B) with 25 mg/day exemestane, and BI 860585 (80–220 mg/day; Arm C) with 60–80 mg/m2 /week paclitaxel, in 28-day cycles. Primary endpoints were the number of patients with dose-limiting toxicities (DLTs) in cycle 1 and the MTD. Forty-one, 25, and 24 patients were treated (Arms A, B, and C). DLTs were observed in four (rash (n = 2), elevated alanine aminotransferase/aspartate aminotransferase, diarrhea), four (rash (n = 3), stomatitis, and increased gamma-glutamyl transferase), and two (diarrhea, increased blood creatine phosphokinase) patients in cycle 1. The BI 860585 MTD was 220 mg/day (Arm A) and 160 mg/day (Arms B and C). Nine patients achieved an objective response (Arm B: Four partial responses (PRs); Arm C: Four PRs; one complete response). The disease control rate was 20%, 28%, and 58% (Arms A, B, and C). The most frequent treatment-related adverse events (AEs) were hyperglycemia (54%) and diarrhea (39%) (Arm A); diarrhea (40%) and stomatitis (40%) (Arm B); fatigue (58%) and diarrhea (58%) (Arm C). The MTD was determined in all arms. Antitumor activity was observed with BI 860585 monotherapy and in combination with exemestane or paclitaxel